Stock AnalizOruka Therapeutics, Inc. ORKA
Biotechnology: In Vitro & In Vivo Diagnostic Substances · data as of November 13, 2026
Oruka Therapeutics, Inc. (ORKA) is a healthcare company listed in the US with a market value of about $7.1B.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -23%.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$105M | -$5M | -$10M | -$19M | -$10M | -$5M | -$8M | -$18M | -$16M | -$11M |
| Free cash flow | -$88M | -$5M | -$11M | -$19M | -$8M | -$5M | -$8M | -$17M | -$15M | -$11M |
| EPS (diluted) | $-1.55 | $-0.37 | $-0.69 | $-1.39 | $-2.07 | $-4.15 | $-10.31 | $-31.86 | $-32.58 | $-32.76 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -20.3% | -15.4% | -19.9% | -37.5% | -20.8% | -73.9% | -134.1% | -181.5% | -74.9% | -23.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $156.17, 48% above the current price; targets range from $117.00 to $200.00; the consensus rating is “Strong buy”; expected EPS is $-2.55 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Oruka Therapeutics pay a dividend?
Not currently.
Is Oruka Therapeutics a good stock to buy?
We do not give buy or sell advice. Oruka Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.